FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

William Charman

Research Profile

Chemicals & Drugs

Concepts & Ideas

Living Beings

Occupations

Chemistry, Pharmaceutical

Anatomy

Physiology

Intestinal Absorption

Procedures

Co-author Network

Publications

TOP 3
Yan Yan Yeap; William N Charman; Tim Quach; Natalie Trevaskis; Patrick Tso; Christopher J H Porter
Intestinal Bile Secretion Promotes Drug Absorption from Lipid Colloidal Phases via Induction of Supersaturation.
Hywel D Williams; Susan A Charman; William N Charman; Colin W Pouton; Ravi M Shanker; Natalie Trevaskis; Christopher J H Porter
Strategies to address low drug solubility in discovery and development.
Suzanne M Caliph; William N Charman; Natalie Trevaskis; Christopher J H Porter
Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: implications for lymphatic transport and absolute bioavailability studies.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of William Charman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Yan Yan Yeap; William N Charman; Tim Quach; Natalie Trevaskis; Patrick Tso; Christopher J H Porter
Intestinal Bile Secretion Promotes Drug Absorption from Lipid Colloidal Phases via Induction of Supersaturation.
Molecular pharmaceutics 2013;10(5):1874-89.
2013: Hywel D Williams; Susan A Charman; William N Charman; Colin W Pouton; Ravi M Shanker; Natalie Trevaskis; Christopher J H Porter
Strategies to address low drug solubility in discovery and development.
Pharmacological reviews 2013;65(1):315-499.
2012: Suzanne M Caliph; William N Charman; Natalie Trevaskis; Christopher J H Porter
Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: implications for lymphatic transport and absolute bioavailability studies.
Journal of pharmaceutical sciences 2012;101(9):3540-6.
2011: Susan A Charman; Sarah Arbe-Barnes; Ian C Bathurst; Reto Brun; Michael Campbell; William N Charman; Francis C K Chiu; Jacques Chollet; J Carl Craft; Darren J Creek; Yuxiang Dong; Hugues Matile; Melanie Maurer; Julia Morizzi; Tien Nguyen; Petros Papastogiannidis; Christian Scheurer; David M Shackleford; Kamaraj Sriraghavan; Lukas Stingelin; Yuanqing Tang; Heinrich Urwyler; Xiaofang Wang; Karen L White; Sergio Wittlin; Lin Zhou; Jonathan L Vennerstrom
Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(11):4400-5.
2010: Natalie Trevaskis; William N Charman; Christopher J H Porter
Targeted drug delivery to lymphocytes: a route to site-specific immunomodulation?
Molecular pharmaceutics 2010;7(6):2297-309.
2010: Natalie Trevaskis; Ravi M Shanker; William N Charman; Christopher J H Porter
The mechanism of lymphatic access of two cholesteryl ester transfer protein inhibitors (CP524,515 and CP532,623) and evaluation of their impact on lymph lipoprotein profiles.
Pharmaceutical research 2010;27(9):1949-64.
2010: Natalie Trevaskis; Claire L McEvoy; Michelle P McIntosh; Glenn A Edwards; Ravi M Shanker; William N Charman; Christopher J H Porter
The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623).
Pharmaceutical research 2010;27(5):878-93.
2010: Yuanqing Tang; Sergio Wittlin; Susan A Charman; Jacques Chollet; Francis C K Chiu; Julia Morizzi; Lisa M Johnson; Josefina Santo Tomas; Christian Scheurer; Chistopher Snyder; Lin Zhou; Yuxiang Dong; William N Charman; Hugues Matile; Heinrich Urwyler; Arnulf Dorn; Jonathan L Vennerstrom
The comparative antimalarial properties of weak base and neutral synthetic ozonides.
Bioorganic & medicinal chemistry letters 2010;20(2):563-6.
2010: Yuxiang Dong; Sergio Wittlin; Kamaraj Sriraghavan; Jacques Chollet; Susan A Charman; William N Charman; Christian Scheurer; Heinrich Urwyler; Josefina Santo Tomas; Christopher Snyder; Darren J Creek; Julia Morizzi; Maria Koltun; Hugues Matile; Xiaofang Wang; Maniyan Padmanilayam; Yuanqing Tang; Arnulf Dorn; Reto Brun; Jonathan L Vennerstrom
The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).
Journal of medicinal chemistry 2010;53(1):481-91.
2009: Karen L White; Gary Nguyen; William N Charman; Glenn A Edwards; W A Fried Faassen; Christopher J H Porter
Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU.
The Journal of pharmacology and experimental therapeutics 2009;331(2):700-9.
2009: Darren J Creek; Eileen Ryan; William N Charman; Francis C K Chiu; Richard J Prankerd; Jonathan L Vennerstrom; Susan A Charman
Stability of peroxide antimalarials in the presence of human hemoglobin.
Antimicrobial agents and chemotherapy 2009;53(8):3496-500.
2008: Jennifer L Marriott; Roger L Nation; Louis Roller; Marian Costelloe; Kirstie Galbraith; Peter Stewart; William N Charman
Pharmacy education in the context of Australian practice.
American journal of pharmaceutical education 2008;72(6):131.
2008: Darren J Creek; David K Chalmers; William N Charman; Brian J Duke
Quantum chemical study of the intermediate complex required for iron-mediated reactivity and antimalarial activity of dispiro-1,2,4-trioxolanes.
Journal of molecular graphics & modelling 2008;27(3):394-400.
2008: Darren J Creek; William N Charman; Francis C K Chiu; Richard J Prankerd; Yuxiang Dong; Jonathan L Vennerstrom; Susan A Charman
Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials.
Antimicrobial agents and chemotherapy 2008;52(4):1291-6.
2008: Natalie Trevaskis; William N Charman; Christopher J H Porter
Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update.
Advanced drug delivery reviews 2008;60(6):702-16.
2008: Lin Zhou; André Alker; Armin Ruf; Xiaofang Wang; Francis C K Chiu; Julia Morizzi; Susan A Charman; William N Charman; Christian Scheurer; Sergio Wittlin; Yuxiang Dong; Daniel Hunziker; Jonathan L Vennerstrom
Characterization of the two major CYP450 metabolites of ozonide (1,2,4-trioxolane) OZ277.
Bioorganic & medicinal chemistry letters 2008;18(5):1555-8.
2008: Jean Cuiné; Claire L McEvoy; William N Charman; Colin W Pouton; Glenn A Edwards; Hassan Benameur; Christopher J H Porter
Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs.
Journal of pharmaceutical sciences 2008;97(2):995-1012.
2007: Greg A Kossena; William N Charman; Clive G Wilson; Bridget O'Mahony; Blythe Lindsay; John Hempenstall; Christopher L Davison; Patrick J Crowley; Christopher J H Porter
Low dose lipid formulations: effects on gastric emptying and biliary secretion.
Pharmaceutical research 2007;24(11):2084-96.
2007: Darren J Creek; William N Charman; Francis C K Chiu; Richard J Prankerd; Kevin J McCullough; Yuxiang Dong; Jonathan L Vennerstrom; Susan A Charman
Iron-mediated degradation kinetics of substituted dispiro-1,2,4-trioxolane antimalarials.
Journal of pharmaceutical sciences 2007;96(11):2945-56.
2007: James Horne; Edward J d'Auvergne; Murray Coles; Tony Velkov; Yanni Chin; William N Charman; Richard J Prankerd; Paul R Gooley; Martin Scanlon
Probing the flexibility of the DsbA oxidoreductase from Vibrio cholerae--a 15N - 1H heteronuclear NMR relaxation analysis of oxidized and reduced forms of DsbA.
Journal of molecular biology 2007;371(3):703-16.
2007: Jean Cuiné; William N Charman; Colin W Pouton; Glenn A Edwards; Christopher J H Porter
Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs.
Pharmaceutical research 2007;24(4):748-57.
2007: Christopher J H Porter; Natalie Trevaskis; William N Charman
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs.
Nature reviews. Drug discovery 2007;6(3):231-48.
2007: Yuanqing Tang; Yuxiang Dong; Sergio Wittlin; Susan A Charman; Jacques Chollet; Francis C K Chiu; William N Charman; Hugues Matile; Heinrich Urwyler; Arnulf Dorn; Saroj Bajpai; Xiaofang Wang; Maniyan Padmanilayam; Jean M Karle; Reto Brun; Jonathan L Vennerstrom
Weak base dispiro-1,2,4-trioxolanes: potent antimalarial ozonides.
Bioorganic & medicinal chemistry letters 2007;17(5):1260-5.
2006: Maniyan Padmanilayam; Bernard Scorneaux; Yuxiang Dong; Jacques Chollet; Hugues Matile; Susan A Charman; Darren J Creek; William N Charman; Josefina Santo Tomas; Christian Scheurer; Sergio Wittlin; Reto Brun; Jonathan L Vennerstrom
Antimalarial activity of N-alkyl amine, carboxamide, sulfonamide, and urea derivatives of a dispiro-1,2,4-trioxolane piperidine.
Bioorganic & medicinal chemistry letters 2006;16(21):5542-5.
2006: Yuxiang Dong; Yuanqing Tang; Jacques Chollet; Hugues Matile; Sergio Wittlin; Susan A Charman; William N Charman; Josefina Santo Tomas; Christian Scheurer; Christopher Snyder; Bernard Scorneaux; Saroj Bajpai; Scott A Alexander; Xiaofang Wang; Maniyan Padmanilayam; Srinivasa R Cheruku; Reto Brun; Jonathan L Vennerstrom
Effect of functional group polarity on the antimalarial activity of spiro and dispiro-1,2,4-trioxolanes.
Bioorganic & medicinal chemistry 2006;14(18):6368-82.
2006: Natalie Trevaskis; Chun Min Lo; Li Yun Ma; Patrick Tso; Helen R Irving; Christopher J H Porter; William N Charman
An acute and coincident increase in FABP expression and lymphatic lipid and drug transport occurs during intestinal infusion of lipid-based drug formulations to rats.
Pharmaceutical research 2006;23(8):1786-96.
2006: Leab Sek; Ben J Boyd; William N Charman; Christopher J H Porter
Examination of the impact of a range of Pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone.
The Journal of pharmacy and pharmacology 2006;58(6):809-20.
2006: Natalie Trevaskis; Christopher J H Porter; William N Charman
An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(5):729-33.
2006: Christine S Perry; Susan A Charman; Richard J Prankerd; Francis C K Chiu; Yuxiang Dong; Jonathan L Vennerstrom; William N Charman
Chemical kinetics and aqueous degradation pathways of a new class of synthetic ozonide antimalarials.
Journal of pharmaceutical sciences 2006;95(4):737-47.
2006: Natalie Trevaskis; Patrick Tso; Therese Rider; William N Charman; Christopher J H Porter; Ronald J Jandacek
Tissue uptake of DDT is independent of chylomicron metabolism.
Archives of toxicology 2006;80(4):196-200.
2006: Joseph A Nicolazzo; Susan A Charman; William N Charman
Methods to assess drug permeability across the blood-brain barrier.
The Journal of pharmacy and pharmacology 2006;58(3):281-93.
2006: Susan A Charman; Christine S Perry; Francis C K Chiu; Kylie A McIntosh; Richard J Prankerd; William N Charman
Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin.
Journal of pharmaceutical sciences 2006;95(2):256-67.
2006: Natalie Trevaskis; Christopher J H Porter; William N Charman
The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport.
The Journal of pharmacology and experimental therapeutics 2006;316(2):881-91.
2006: Nathalie L Leveque; William N Charman; Francis C K Chiu
Sensitive method for the quantitative determination of proguanil and its metabolites in rat blood and plasma by liquid chromatography-mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;830(2):314-21.
2006: Christine S Perry; Susan A Charman; Richard J Prankerd; Francis C K Chiu; Martin Scanlon; David Chalmers; William N Charman
The binding interaction of synthetic ozonide antimalarials with natural and modified beta-cyclodextrins.
Journal of pharmaceutical sciences 2006;95(1):146-58.
2005: Natalie Trevaskis; Christopher J H Porter; William N Charman
Bile increases intestinal lymphatic drug transport in the fasted rat.
Pharmaceutical research 2005;22(11):1863-70.
2005: Darren J Creek; Francis C K Chiu; Richard J Prankerd; Susan A Charman; William N Charman
Kinetics of iron-mediated artemisinin degradation: effect of solvent composition and iron salt.
Journal of pharmaceutical sciences 2005;94(8):1820-9.
2005: Yuxiang Dong; Jacques Chollet; Hugues Matile; Susan A Charman; Francis C K Chiu; William N Charman; Bernard Scorneaux; Heinrich Urwyler; Josefina Santo Tomas; Christian Scheurer; Christopher Snyder; Arnulf Dorn; Xiaofang Wang; Jean M Karle; Yuanqing Tang; Sergio Wittlin; Reto Brun; Jonathan L Vennerstrom
Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes.
Journal of medicinal chemistry 2005;48(15):4953-61.
2005: Tony Velkov; Sara Chuang; Jerome Wielens; Harry Sakellaris; William N Charman; Christopher J H Porter; Martin Scanlon
The interaction of lipophilic drugs with intestinal fatty acid-binding protein.
The Journal of biological chemistry 2005;280(18):17769-76.
2005: Greg A Kossena; William N Charman; Ben J Boyd; Christopher J H Porter
Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water-soluble drug.
Journal of pharmaceutical sciences 2005;94(3):481-92.
2004: Michael Campbell; Richard J Prankerd; Ashley S Davie; William N Charman
Degradation of berenil (diminazene aceturate) in acidic aqueous solution.
The Journal of pharmacy and pharmacology 2004;56(10):1327-32.
2004: Greg A Kossena; William N Charman; Ben J Boyd; Christopher J H Porter
A novel cubic phase of medium chain lipid origin for the delivery of poorly water soluble drugs.
Journal of controlled release : official journal of the Controlled Release Society 2004;99(2):217-29.
2004: Jonathan L Vennerstrom; Sarah Arbe-Barnes; Reto Brun; Susan A Charman; Francis C K Chiu; Jacques Chollet; Yuxiang Dong; Arnulf Dorn; Daniel Hunziker; Hugues Matile; Kylie McIntosh; Maniyan Padmanilayam; Josefina Santo Tomas; Christian Scheurer; Bernard Scorneaux; Yuanqing Tang; Heinrich Urwyler; Sergio Wittlin; William N Charman
Identification of an antimalarial synthetic trioxolane drug development candidate.
Nature 2004;430(7002):900-4.
2004: Christopher J H Porter; Ann Marie Kaukonen; Ben J Boyd; Glenn A Edwards; William N Charman
Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation.
Pharmaceutical research 2004;21(8):1405-12.
2004: Christopher J H Porter; Ann Marie Kaukonen; Agnes Taillardat-Bertschinger; Ben J Boyd; Jacquelyn M O'Connor; Glenn A Edwards; William N Charman
Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine.
Journal of pharmaceutical sciences 2004;93(5):1110-21.
2004: Michelle P McIntosh; William N Charman; Michael Campbell; Christopher J H Porter
Influence of physicochemical properties on the patterns of association of a series of aliphatic esters of halofantrine with plasma lipoproteins.
Journal of controlled release : official journal of the Controlled Release Society 2004;95(2):275-89.
2004: Ann Marie Kaukonen; Ben J Boyd; William N Charman; Christopher J H Porter
Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids.
Pharmaceutical research 2004;21(2):254-60.
2004: Ann Marie Kaukonen; Ben J Boyd; Christopher J H Porter; William N Charman
Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations.
Pharmaceutical research 2004;21(2):245-53.
2004: Greg A Kossena; William N Charman; Ben J Boyd; Dave E Dunstan; Christopher J H Porter
Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: a phase diagram approach.
Journal of pharmaceutical sciences 2004;93(2):332-48.
2004: Michelle P McIntosh; Andrew J Batey; Susan J Coker; Christopher J H Porter; William N Charman
Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetized rabbit model.
The Journal of pharmacy and pharmacology 2004;56(1):69-77.
2003: Agnes Taillardat-Bertschinger; Christine S Perry; Alexandra Galland; Richard J Prankerd; William N Charman
Partitioning of halofantrine hydrochloride between water, micellar solutions, and soybean oil: Effects on its apparent ionization constant.
Journal of pharmaceutical sciences 2003;92(11):2217-28.
2003: Shui-Mei Khoo; David M Shackleford; Christopher J H Porter; Glenn A Edwards; William N Charman
Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs.
Pharmaceutical research 2003;20(9):1460-5.
2003: Brendan M Johnson; William N Charman; Christopher J H Porter
Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(9):1151-60.
2003: David M Shackleford; W A Faassen; Natalie Houwing; Holger Lass; Glenn A Edwards; Christopher J H Porter; William N Charman
Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs.
The Journal of pharmacology and experimental therapeutics 2003;306(3):925-33.
2003: Ben J Boyd; Christopher J H Porter; William N Charman
Using the polymer partitioning method to probe the thermodynamic activity of poorly water-soluble drugs solubilized in model lipid digestion products.
Journal of pharmaceutical sciences 2003;92(6):1262-71.
2003: David M Shackleford; Christopher J H Porter; William N Charman
Does stereoselective lymphatic absorption contribute to the enantioselective pharmacokinetics of halofantrine In Vivo?
Biopharmaceutics & drug disposition 2003;24(4):153-7.
2003: Brendan M Johnson; Weiqing Chen; Ronald T Borchardt; William N Charman; Christopher J H Porter
A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum.
The Journal of pharmacology and experimental therapeutics 2003;305(1):151-8.
2003: David M Shackleford; Richard J Prankerd; Martin Scanlon; William N Charman
Self-micellization of gemfibrozil 1-O-beta acyl glucuronide in aqueous solution.
Pharmaceutical research 2003;20(3):465-70.
2003: Michelle P McIntosh; Andrew J Batey; Christopher J H Porter; William N Charman; Susan J Coker
Desbutylhalofantrine: evaluation of QT prolongation and other cardiovascular effects after intravenous administration in vivo.
Journal of cardiovascular pharmacology 2003;41(3):406-13.
2003: Greg A Kossena; Ben J Boyd; Christopher J H Porter; William N Charman
Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs.
Journal of pharmaceutical sciences 2003;92(3):634-48.
2002: Shui-Mei Khoo; Richard J Prankerd; Glenn A Edwards; Christopher J H Porter; William N Charman
A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs.
Journal of pharmaceutical sciences 2002;91(3):647-59.
2002: Brendan M Johnson; William N Charman; Christopher J H Porter
An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine.
AAPS pharmSci 2002;4(4):E40.
2002: Margaret M Doherty; William N Charman
The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?
Clinical pharmacokinetics 2002;41(4):235-53.
2002: Leab Sek; Christopher J H Porter; Ann Marie Kaukonen; William N Charman
Evaluation of the in-vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products.
The Journal of pharmacy and pharmacology 2002;54(1):29-41.
2001: Brendan M Johnson; William N Charman; Christopher J H Porter
The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil.
The Journal of pharmacy and pharmacology 2001;53(12):1611-9.
2001: Shui-Mei Khoo; Glenn A Edwards; Christopher J H Porter; William N Charman
A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine.
Journal of pharmaceutical sciences 2001;90(10):1599-607.
2001: Christopher J H Porter; William N Charman
In vitro assessment of oral lipid based formulations.
Advanced drug delivery reviews 2001;50 Suppl 1():S127-47.
2001: Christopher J H Porter; William N Charman
Intestinal lymphatic drug transport: an update.
Advanced drug delivery reviews 2001;50(1-2):61-80.
2001: Glenn A Edwards; Christopher J H Porter; S M Caliph; Shui-Mei Khoo; William N Charman
Animal models for the study of intestinal lymphatic drug transport.
Advanced drug delivery reviews 2001;50(1-2):45-60.
2001: Christopher J H Porter; William N Charman
Transport and absorption of drugs via the lymphatic system.
Advanced drug delivery reviews 2001;50(1-2):1-2.
2001: Leab Sek; Christopher J H Porter; William N Charman
Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis.
Journal of pharmaceutical and biomedical analysis 2001;25(3-4):651-61.
2000: Shui-Mei Khoo; Christopher J H Porter; William N Charman
The formulation of Halofantrine as either non-solubilizing PEG 6000 or solubilizing lipid based solid dispersions: physical stability and absolute bioavailability assessment.
International journal of pharmaceutics 2000;205(1-2):65-78.
2000: S M Caliph; William N Charman; Christopher J H Porter
Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats.
Journal of pharmaceutical sciences 2000;89(8):1073-84.
2000: William N Charman
Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts.
Journal of pharmaceutical sciences 2000;89(8):967-78.
2000: K C Lyons; William N Charman; R Miller; Christopher J H Porter
Factors limiting the oral bioavailability of N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP) and enhancement of absorption in rats by delivery in a water-in-oil microemulsion.
International journal of pharmaceutics 2000;199(1):17-28.
1999: Michelle P McIntosh; Christopher J H Porter; Kishor M Wasan; Manisha Ramaswamy; William N Charman
Differences in the lipoprotein binding profile of halofantrine in fed and fasted human or beagle plasma are dictated by the respective masses of core apolar lipoprotein lipid.
Journal of pharmaceutical sciences 1999;88(3):378-84.
1999: Kishor M Wasan; Manisha Ramaswamy; Michelle P McIntosh; Christopher J H Porter; William N Charman
Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: in vitro studies in normolipidemic and dyslipidemic human plasmas.
Journal of pharmaceutical sciences 1999;88(2):185-90.
1998: Shui-Mei Khoo; J H Porter; Glenn A Edwards; William N Charman
Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole.
Journal of pharmaceutical sciences 1998;87(12):1538-41.
1998: Kylie A McIntosh; Susan A Charman; L A Borgen; William N Charman
Analytical methods and stability assessment of liquid yeast derived sucrase.
Journal of pharmaceutical and biomedical analysis 1998;17(6-7):1037-45.
1998: A J Humberstone; Christopher J H Porter; Glenn A Edwards; William N Charman
Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state.
Journal of pharmaceutical sciences 1998;87(8):936-42.
1998: Kylie A McIntosh; William N Charman; Susan A Charman
The application of capillary electrophoresis for monitoring effects of excipients on protein conformation.
Journal of pharmaceutical and biomedical analysis 1998;16(6):1097-105.
1998: A J Humberstone; Alan F Cowman; J Horton; William N Charman
Effect of altered serum lipid concentrations on the IC50 of halofantrine against Plasmodium falciparum.
Journal of pharmaceutical sciences 1998;87(2):256-8.
1997: Christopher J H Porter; S M Caliph; William N Charman
Differences in pre- and post-prandial plasma lipid profiles affect the extraction efficiency of a model highly lipophilic drug from beagle dog plasma.
Journal of pharmaceutical and biomedical analysis 1997;16(1):175-80.
1997: William N Charman; Christopher J H Porter; S Mithani; J B Dressman
Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH.
Journal of pharmaceutical sciences 1997;86(3):269-82.
1996: M M Doherty; P J Hughes; Susan A Charman; K V Brock; N V Korszniak; William N Charman
Biphasic drug absorption from the epidural space of the dog may limit the utility of a slow release medium molecular weight hyaluronic acid-lidocaine ionic complex formulation.
Anesthesia and analgesia 1996;83(6):1244-50.
1996: A J Humberstone; Christopher J H Porter; William N Charman
A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine.
Journal of pharmaceutical sciences 1996;85(5):525-9.
1996: Christopher J H Porter; S A Charman; A J Humberstone; William N Charman
Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion.
Journal of pharmaceutical sciences 1996;85(4):357-61.
1996: Christopher J H Porter; S A Charman; William N Charman
Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion.
Journal of pharmaceutical sciences 1996;85(4):351-6.
1996: Christopher J H Porter; William N Charman
Model systems for intestinal lymphatic transport studies.
Pharmaceutical biotechnology 1996;8():85-102.
1995: M M Doherty; P J Hughes; N V Korszniak; William N Charman
Prolongation of lidocaine-induced epidural anesthesia by medium molecular weight hyaluronic acid formulations: pharmacodynamic and pharmacokinetic studies in the rabbit.
Anesthesia and analgesia 1995;80(4):740-6.
1995: A J Humberstone; G J Currie; Christopher J H Porter; M J Scanlon; William N Charman
A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions.
Journal of pharmaceutical and biomedical analysis 1995;13(3):265-72.
1994: L E Bennett; William N Charman; D B Williams; S A Charman
Analysis of bovine immunoglobulin G by capillary gel electrophoresis.
Journal of pharmaceutical and biomedical analysis 1994;12(9):1103-8.
1993: S A Charman; L E McCrossin; William N Charman
Validation of a peptide map for recombinant porcine growth hormone and application to stability assessment.
Pharmaceutical research 1993;10(10):1471-7.
1993: S A Charman; K L Mason; William N Charman
Techniques for assessing the effects of pharmaceutical excipients on the aggregation of porcine growth hormone.
Pharmaceutical research 1993;10(7):954-62.
1993: P J Hughes; M M Doherty; William N Charman
A rabbit model for the evaluation of epidurally administered local anaesthetic agents.
Anaesthesia and intensive care 1993;21(3):298-303.
1992: William N Charman; A J Humberstone; S A Charman
Analysis of pilocarpine and its degradation products by micellar electrokinetic capillary chromatography.
Pharmaceutical research 1992;9(9):1219-23.
1991: William N Charman; C S Lai; Barrie C Finnin; Barry L Reed
Self-association of nicotinamide in aqueous solution: mass transport, freezing-point depression, and partition coefficient studies.
Pharmaceutical research 1991;8(9):1144-50.